William Parsons, MD
Interventional Cardiology · Raleigh, NCNPI 1437158508
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GI Supply, Inc. accounts for 93.1% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for interventional cardiology clinicians in NC, where the typical reported total is $5,390.
Across 4 payments — averaging $150.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GI Supply, Inc.$561
- Abiomed$41
Across 1 payment — averaging $91.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$92
What the payments were for
- Food & beverage$602100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GI Supply, Inc. | 3 | $561 |
| Abiomed | 1 | $41 |
How this compares
$602 in reported general payments places this provider in the 10th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 833 | $839,887 |
| Repatha SureclickEvolocumab | 250 | $264,137 |
| EntrestoSacubitril/Valsartan | 167 | $162,667 |
| JardianceEmpagliflozin | 136 | $125,689 |
| XareltoRivaroxaban | 74 | $105,086 |
| Praluent PenAlirocumab | 49 | $43,233 |
| FarxigaDapagliflozin Propanediol | 37 | $28,356 |
| Ezetimibe | 768 | $14,980 |
| VascepaIcosapent Ethyl | 20 | $10,717 |
| Rosuvastatin Calcium | 812 | $10,066 |
| Metoprolol Succinate | 747 | $8,945 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 21 | $6,091 |
| Flecainide Acetate | 129 | $6,081 |
| Atorvastatin Calcium | 613 | $5,744 |
| Telmisartan | 160 | $5,698 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Raleigh
- Ravish SacharRaleigh$1.6M
- Robert JobeRaleigh$191K
- James ZidarRaleigh$57K
- Willis WuRaleigh$56K
- Islam OthmanRaleigh$50K
- Andrew SampsonRaleigh$48K
- Dwijesh PatelRaleigh$40K
- Siva KethaRaleigh$19K
- Mohit PasiRaleigh$16K
- George AdamsGarner$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.